A. De Matteis

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 497 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +16

Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study

W. Jonat, M. Kaufmann, Willi Sauerbrei et al. · Journal of Clinical Oncology · 2002 · 338 citations

Medicine, Oncology, Pharmacotherapy +13

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

Giorgio Mustacchi, Rita Ceccherini, Stefano Milani et al. · Annals of Oncology · 2003 · 203 citations · Full text

Medicine, Geriatric Medicine, Oncology +10

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno et al. · Journal of Clinical Oncology · 2004 · 165 citations · Full text

Medicine, Oncology, Pharmacology +15